Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2019
Trust Is the Key Ingredient in Medicaid Value-Based Contracts, Manufacturers and Payers Agree
March 26, 2019
Keeping an Eye on Increasing Competition in the Specialty Drug Pipeline
March 27, 2019
Dr Sebastian Schneeweiss on How Rapid-Cycle Analytics Can Identify High-Risk, High-Cost Patients
March 27, 2019
Dr Crescent Moore Outlines Part D Changes to Expect in 2020
March 27, 2019
The Balancing Act of Using Pharmacy Strategies to Fight the Opioid Epidemic
March 27, 2019
Current and Future Status of Drug Pricing Reform as the Blueprint Approaches the 1-Year Mark
March 27, 2019
Dr Steven Pearson: ICER Can Provide More Information When a Drug is Approved With Limited Data
March 28, 2019
Sophie Schmitz on the Importance of Considering Value of Gene Therapies, Not Just Cost
March 28, 2019
Managing Cholesterol With PCSK9 Inhibitors and Overcoming Operational Challenges in Practice
March 28, 2019
Dr James Chambers Discusses Variability in Specialty Drug Coverage and Its Impact
March 29, 2019
Dr Michael Steinman Discusses Effective Strategies for Improving Medication Management
March 29, 2019
Costs of Living With HIV Can Be Mitigated by Rapid Initiation of ART Post Diagnosis
March 29, 2019
Real-Time Prescription Benefit Checks Could Provide Accurate Cost Estimates at the Point of Prescribing
April 01, 2019
Dr Brian MacDonald Explains How Technology Can Improve Patient Management Strategies
April 10, 2019
Dr Crescent Moore on the Effect of Step Therapy in MA Plans, Other Formulary Regulations
April 13, 2019
Dr Michael Steinman on the Importance of Medication Management Strategies for Older Adults
April 15, 2019
Dr Sebastian Schneeweiss: How Payers Can Benefit From Rapid-Cycle Analytics of Real-World Evidence
April 19, 2019
Dr Crescent Moore on Implementing Care Coordination Programs in Medicare
April 25, 2019
Dr Sebastian Schneeweiss Discusses How Rapid-Cycle Analytics Can Evaluate Drug Safety, Efficacy
May 01, 2019
Dr Michael Steinman Details Opportunities for Improving Medication Management Strategies
May 05, 2019
Dr Crescent Moore Outlines CMS' Efforts to Address the Opioid Epidemic
May 13, 2019
Dr Sebastian Schneeweiss: In 5 Years, Rapid-Cycle Analytics Will Account for Majority of Analyses
May 15, 2019
Currently Reading
Dr Jane Barlow on Innovations, Limitations Within Alternative Payment Models
January 14, 2020

Dr Jane Barlow on Innovations, Limitations Within Alternative Payment Models

At the end of the day, the focus should be on improving the efficiency of our healthcare system and bringing cost-effective care to patients, said Jane Barlow, MD, MPH, MBA, EVP and Chief Clinical Officer for Real Endpoints.


At the end of the day, the focus should be on improving the efficiency of our healthcare system and bringing cost-effective care to patients, said Jane Barlow, MD, MPH, MBA, EVP and Chief Clinical Officer for Real Endpoints.

Transcript

Do you have a particular financing mechanism that you think has the most chance of being successful?

No, I don’t think there’s any one that’s going to emerge as the winner. I personally, because I'm a clinician, like the focus on outcomes and particularly meaningful outcomes that are improvements of health, or at least maintaining health and not having a deterioration. But I think there’s going to be a lot of different dependencies based on the payer, the different drug attributes, and other factors that may make one model work in one situation or another model work in another situation. At the end of the day, they really all should be focused on improving the efficiency of our healthcare system and bringing the best care to patients that they can at the lowest cost, but MEWS [modified early warning score] gives a lot of different ways you could get there.

Therapies are not the only area where alternative payment models are needed: what is happening in the diagnostic and genetic testing space?

There’s some interesting work that’s been going on in diagnostics. One example of a value-based deal in that area is one that occurred between Harvard Pilgrim and Illumina to offer trisomy testing, so noninvasive pregnancy testing for women under age 35 of average risk. They did a risk-based deal and showed that they had more anti-PTEN testing done, but they reduced invasive testing and they reduced overall testing. So, I think it’s better care for women and a better use of our resources in the healthcare system.

What are some limitations to alternative payment models that still need to be hammered out?

One of the biggest disconnects is the measures that we use for clinical trials, and approval of drugs may be very different than what’s practically attainable through claims data or even testing that a physician would do in their office and be able to report back. So, I think earlier on in the clinical trials, we really need to be thinking about how to bridge some of those outcome metrics to metrics that are attainable in the real world so that you can have a firm basis on which to do an outcomes-based agreement.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up